A controlled trial of a human papillomavirus type 16 vaccine.

By L. Koutsky, K. Ault, C. Wheeler, Darron R. Brown, E. Barr, F. Alvarez, L. Chiacchierini, K. Jansen. New England Journal of Medicine, 2002

1,817 citations recorded by the source corpus.

Subfields: Epidemiology, Otorhinolaryngology, Surgery

View Paper: https://www.semanticscholar.org/paper/30364ed4430462cd41abdcbcefed970ca411e9a3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Silvia Franceschi
2. G. Clifford
3. X. Castellsagué
4. M. Stanley
5. Luisa Lina Villa
6. L. Laimins
7. J. Doorbar

In Otorhinolaryngology

1. X. Castellsagué

In Surgery

1. Silvia Franceschi
2. M. Stanley
3. Luisa Lina Villa

Citations in the corpus

• Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. (2003, background): “The prospect of HPV vaccine development ( 38 ) offers hope for prevention of cervical and anogenital cancers and possibly also for a substantial number of cancers of the oropharynx and oral cavity.”
• High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up (2006, methodology): “The quadrivalent vaccine consisted of a mixture of four recombinant HPV type-specific VLPs composed of the L1 major capsid proteins of HPV types 6, 11, 16, and 18 synthesised in Saccharomyces cerevisiae (Lowe et al, 1997; Koutsky et al, 2002; Ault et al, 2004).”
• Immune responses to human papillomavirus. (2006, result): “This confirms the results of previous trials showing that HPV 16 or HPV 16/18 vaccines confer protection against cervical intraepithelial neoplasia induced by these respective HPV types [61, 62 ], and strongly suggests that anogenital disease induced by HPV 6 or 11 can be controlled.”
• Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis (2003, background): “HPV vaccines hold great promise to reduce the global burden of ICC any potential vaccine be multivalent since prior infection with one type does not appear to decrease the risk of infection by another HPV type (Koutsky et al, 2002; Combita et al, 2002; Liaw et al, 2001).”
• Pathogenesis of Human Papillomaviruses in Differentiating Epithelia (2004, background): “A significant advance in this area has been made through the use of virus-like particle-based vaccines (85).”